Edgewise Therapeutics Inc. (EWTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Edgewise Therapeutics Inc. (EWTX) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How EWTX Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -4.8% | -$167.8K | -$144.1M | -31.8% |
| FY 2024 | $4.00B | 0% | -4% | -$133.8K | -$110.3M | -29.2% |
| FY 2023 | $4.00B | 0% | -2.9% | -$100.2K | -$91.9M | -6.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring EWTX)
- ✓Live walkthrough of EWTX's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
EWTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -1.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on EWTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for EWTX. Explore sector supply chains on /butterfly.
EWTX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Edgewise Therapeutics Inc. (EWTX)?
In FY 2025 (10-K), EWTX converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).